大類學(xué)科: 不限 醫(yī)學(xué) 生物 物理 化學(xué) 農(nóng)林科學(xué) 數(shù)學(xué) 地學(xué)天文 地學(xué) 環(huán)境科學(xué)與生態(tài)學(xué) 綜合性期刊 管理科學(xué) 社會(huì)科學(xué) 查看全部熱門領(lǐng)域
Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology
Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.
《Expert Opinion On Drug Discovery》是一本由TAYLOR & FRANCIS LTD出版商出版的專業(yè)醫(yī)學(xué)期刊,該刊創(chuàng)刊于2006年,刊期Bimonthly,該刊已被國(guó)際權(quán)威數(shù)據(jù)庫(kù)SCIE收錄。在中科院最新升級(jí)版分區(qū)表中,該刊分區(qū)信息為大類學(xué)科:醫(yī)學(xué) 2區(qū),小類學(xué)科:藥學(xué) 2區(qū);在JCR(Journal Citation Reports)分區(qū)等級(jí)為Q1。該刊發(fā)文范圍涵蓋藥學(xué)等領(lǐng)域,旨在及時(shí)、準(zhǔn)確、全面地報(bào)道國(guó)內(nèi)外藥學(xué)工作者在該領(lǐng)域取得的最新研究成果、工作進(jìn)展及學(xué)術(shù)動(dòng)態(tài)、技術(shù)革新等,促進(jìn)學(xué)術(shù)交流,鼓勵(lì)學(xué)術(shù)創(chuàng)新。2021年影響因子為7.05,平均審稿速度較慢,6-12周。
大類學(xué)科 | 分區(qū) | 小類學(xué)科 | 分區(qū) | Top期刊 | 綜述期刊 |
醫(yī)學(xué) | 3區(qū) | PHARMACOLOGY & PHARMACY 藥學(xué) | 3區(qū) | 否 | 是 |
JCR分區(qū)等級(jí) | JCR所屬學(xué)科 | 分區(qū) | 影響因子 |
Q1 | PHARMACOLOGY & PHARMACY | Q1 | 7.05 |
影響因子 | h-index | Gold OA文章占比 | 研究類文章占比 | OA開(kāi)放訪問(wèn) | 平均審稿速度 |
7.05 | 50 | 10.24% | 0.00% | 未開(kāi)放 | 較慢,6-12周 |